NCT01848028Recruiting
PsoBest - The German Psoriasis Registry
Long-Term Benefits and Safety of Systemic Psoriasis Therapy: German Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely confined to systemic therapy in Germany. Systemic therapy includes conventional systemic therapy (e.g. fumaric acids, methotrexate, ciclosporin A) and biological treatment (e.g. adalimumab, etanercept). While short- and middle-term efficacy of most systemic treatments has been shown in clinical studies (and is incorporated in international guidelines), knowledge about long-term outcomes, optimal treatment and effectiveness under real-world conditions is still missing. PsoBest, the German registry on the treatment of moderate to severe Pso and PsA started in 2008 and documents the long-term course of patients being administered any biologic or conventional systemic antipsoriatic drug authorized in Germany for the first time. The registry evaluates the long-term course of 3,500 patients with Pso and PsA treated with systemic antipsoriatics.
- Status (registry)
- Recruiting
- Study type
- Observational
- Enrollment
- 3500 (estimated)
- First submitted
- 7 Apr 2013
- Start date
- 1 Jan 2008
- Primary completion date
- 31 Dec 2032
- Lead sponsor
- Universitätsklinikum Hamburg-Eppendorf
- Diseases
- Psoriasis, Psoriatic arthritis
- NCT number
- NCT01848028
What you commit to
- Study type: Observational
- Planned participants: 3500
- From 1 Jan 2008 to the primary completion date, 31 Dec 2032
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- lack of informed consent
- patients being participants of clinical trials at the day of admission to the registry (if a patient is included into a clinical trial during the registry follow-ups, the patient data will be recorded, but analysed separately)
Who the study is looking for
- patients with diagnosis of plaque-type psoriasis or psoriasis arthritis confirmed by a dermatologist
- age ≥ 18 years
- being administered a specific systemic drug for the first time
- informed consent to participate
- sufficient language skills (German)
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Nationwide group of dermatological centers, hospitals and medical offices Coordinator of this site? Confirm its status | Hamburg | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.